AIDSinfo - Drug Details

A Service of The U.S. Department of Health
and Human Services

Antiretroviral Drugs

Fusion Inhibitors

Enfuvirtide (Fuzeon, T-20)

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Delavirdine (Rescriptor)

Efavirenz (Sustiva)

Nevirapine (Viramune)

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Abacavir (Ziagen)

Abacavir + Lamivudine (Epzicom)

Abacavir+Lamivudine+Zidovudine (Trizivir)

Didanosine (Videx, ddI)

Emtricitabine (Emtriva, FTC)

Emtricitabine + Tenofovir DF (Truvada)

Lamivudine (Epivir, 3TC)

Lamivudine+Zidovudine (Combivir)

Stavudine (Zerit, d4T)

Tenofovir DF (Viread)

Zalcitabine (Hivid, ddC)

Zidovudine (Retrovir, AZT, ZDV)

Protease Inhibitors (PIs)

Amprenavir (Agenerase)

Atazanavir (Reyataz)

Fosamprenavir (Lexiva, 908)

Indinavir (Crixivan)

Lopinavir+Ritonavir (Kaletra)

Nelfinavir (Viracept)

Ritonavir (Norvir)

Saquinavir (Fortovase, Invirase)

Home > Drugs > Combivir

Lamivudine+Zidovudine (Combivir)

Generic Name: Lamivudine+Zidovudine
Brand Name: Combivir

Lamivudine/zidovudine, also known as Combivir, is a combination of the two anti-HIV medicines, lamivudine (Epivir) and zidovudine (Retrovir). Both medicines belong to the class of antiretroviral drugs called nucleoside reverse transcriptase inhibitors (NRTIs). This class of drugs blocks reverse transcriptase, an enzyme (cell protein that helps chemical reactions) that HIV needs to make more copies of itself.

AIDSinfo Drug Record for Lamivudine+Zidovudine

Search the Drug Database

Guidelines References to Lamivudine+Zidovudine

	Adult and Adolescent Guidelines
	Table 12a: Antiretroviral Regimens Recommended for Treatment of HIV-1 Infection in Antiretroviral Naïve Patients
	Table 12b: Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy
	Table 14: Antiretroviral Regimens or Components That Should Not Be Offered At Any Time
	Table 15: Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
	Table 19: Adverse Drug Reactions and Related "Black Box Warnings" in Product Labeling for Antiretroviral Agents
	Table 23: HIV-Related Drugs with Overlapping Toxicities
	Table 30: Preclinical and Clinical Data Concerning the Use of Antiretrovirals During Pregnancy
	Pediatric Guidelines
	Appendix: Characteristics of Available Antiretroviral Drugs
	NRTI Drugs - Pediatrics
	Supplement: Pediatric Antiretroviral Drug Information
	Table 11: Recommended Antiretroviral Regimens for Initial Therapy for HIV Infection in Children
	Table 8: Advantages and Disadvantages of NRTI, NtRTI Combinations for Use in Highly Active Antiretroviral Combination Regimens
	Perinatal Guidelines
	NRTI Drugs - Perinatal
	Table 2: Preclinical and Clinical Data Relevant to the Use of Antiretrovirals During Pregnancy
	Table 3: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy
	Table 5: Comparison of Intrapartum/Postpartum Regimens for HIV-1-Infected Women in Labor Who Have Had No Prior Antiretroviral Therapy (Scenario #3)

Lamivudine+Zidovudine News

No related documents are currently available. Please check back soon. We are continually updating this area of our site.

More About Lamivudine+Zidovudine

	AIDSinfo Drug Record for Combivir
	MEDLINEplus Fact Sheet on Combivir
	Clinical Trials Using Combivir
	Literature Citations for Combivir
	more...